Risk prediction of acute kidney injury by [TIMP-2]•[IGFBP7].

Abstract

Acute kidney injury (AKI) is a common syndrome with increased mortality, a heavy burden of illness and high cost. The Kidney Disease Improving Global Outcomes (KDIGO) criteria for staging of AKI have been validated in large patient cohorts and classify AKI into three stages. In order to achieve prevention or early therapy, the focus of scientific interest is early detection and risk prediction of AKI. The combination of the two cell cycle arrest markers [TIMP-2]·[IGFBP7] in the urine shows good results in the risk prediction of AKI in different clinical settings (intensive care medicine, sepsis, cardiac surgery, emergency department). Clinical use is currently being tested in different randomized intervention studies.

• Authors: M Kimmel, M Schanz, M D Alscher
• Journal: Drugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 53 Issue 6 Pg. 349-356 (Jun 2017) ISSN: 1699-3993 [Print] Spain
• PMID: 28799580 (Publication Type: Journal Article, Review)
• Copyright: Copyright 2017 Clarivate Analytics.

Chemical References

• Biomarkers
• Insulin-Like Growth Factor Binding Proteins
• TIMP2 protein, human
• insulin-like growth factor binding protein-related protein 1
• Tissue Inhibitor of Metalloproteinase-2
• Creatinine

Topics

• Acute Kidney Injury (blood, urine)
• Biomarkers
• Cardiac Surgical Procedures
• Clinical Trials as Topic
• Creatinine (blood)
• Emergencies
• Humans
• Insulin-Like Growth Factor Binding Proteins (urine)
• Postoperative Complications (urine)
• Predictive Value of Tests
• Risk Assessment
• Sepsis (urine)
• Tissue Inhibitor of Metalloproteinase-2 (urine)
• Urinalysis (methods)